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Abstract  
Breast carcinoma is one of the commonest malignancies in females. It is curable, if detected, at an early stage. Levels of 
serum ferritin and nitric oxide are found raised in various cancers including breast carcinoma. These parameters are 
sufficiently interlinked to be used as markers for breast cancer. In this study, the levels of ferritin and nitric oxide were 
estimated in 30 patients of early stage (stage I and II) and 30 patients of advanced breast cancer (stge III and IV). These 
levels were compared with 30 healthy females as controls. Serum ferritin and nitric oxide were found to be raised 
(p<0.001) in all breast cancer patients as compared to controls. The rise in their levels was significantly more in advanced 
stage as compared to early stage carcinoma (p<0.001). Treatment had a curative effect on these parameters also as shown 
by a decrease in their levels in both the groups. Thus, estimation of ferritin and nitric oxide may aid in diagnosis, 
assessment of severity and monitoring of breast cancer patients though results will be highly reliable in conjunction with 
other tumor markers. 
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Introduction 
The most important function of ferritin is in iron 
storage but it performs a number of other 
significant biological functions in the body. It has, 
recently, been implicated in the pathogenesis of a 
number of diseases including cancer. A number 
of mechanisms such as pro-oxidant and 
pro-inflammatory pathways are responsible for 
this [1]. Secretion of ferritin is stimulated by 
cytokines. Cytokines play an important role in 
causation of cancer and ferritin plays a prominent 
role in cytokine response [2]. 
Oxidants induce ferritin transcription by 
directly targeting conserved region of ferritin 
genes. These oxidants, including nitric oxide 
(NO), may release iron from ferritin either 
directly or through heme oxygenase [3,4] 
Cytokines may also affect ferritin translation 
indirectly through their ablity to induce the 
enzyme inducible nitric oxide synthase (iNOS) 
and increase NO which, in turn, causes the 
activation of iron regulatory proteins 1 and 2 
(IRP 1 and IRP 2) [2,4]. It has been reported that 
high levels of NO may be cytostatic or cytotoxic 
for tumor cells while low levels may have the 
opposite effect and promote tumor growth. NO 
has genotoxic and angiogenic properties and also 
modulates tumor deoxyribonucleic acid (DNA) 
repair mechanisms. It may mediate induction of 
ferritin synthesis by selective IRP 2 
downregulation [5,6]. 
Breast cancer is the most common malignant 
disease and is the chief cause of cancer related 
mortality among women worldwide [7]. In India, 
breast cancer is the second most common cancer 
overall (both sexes) and second most common 
cancer in incidence and mortality next only to 
cervix carcinoma [8]. It accounts for around 9% 
of all cancers seen in Department of 
Radiotherapy of our institute [9]. The standard 
management of breast cancer is by means of 
combined modality which includes locoregional 
treatment (surgery and radiotherapy) and 
systemic treatment (chemotherapy, hormonal 
therapy and targeted therapy) [10]. The tumor 
markers in breast carcinoma like CA 15-3 and 
carcinoembryonic antigen (CEA) are generally 
useful in the follow-up of the patients with 
metastatic disease in combination with other 
diagnostic techniques. This disease is still in the 
need of more precise biomarkers which might 
help in early detection, assessment of severity 
and for prediction of therapy response [7].  
Therefore, this study was planned to estimate 
the levels of ferritin and NO in patients of breast 
cancer as both these parameters are interrelated 
and are markers of inflammation, iron 
metabolism, cell proliferation, angiogenesis and 
vasomotor activity which are generally found 
disturbed in malignancies.  
Material and methods 
Ninety females were enrolled for this study. Out 
of these, 60 were patients of newly diagnosed/ 
untreated histopathologically proven breast 
cancer and 30 were healthy, non-anaemic 
females of age more than 15 years. Informed 
consent from all the subjects and approval from 
institutional board of postgraduate studies was 
obtained beforehand. The pre-treatment 
evaluation included complete history, general 
physical examination, routine biochemical and 
hematological investigations and appropriate 
radiological assessment (chest X-ray, 
ultrasonography of abdomen and pelvis for all 
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patients and computed tomography scan of chest 
and abdomen whenever indicated). The patients 
were staged according to American Joint 
Committee of Cancer (AJCC) staging 2010 
(TNM). Pregnant or lactating females and those 
with any associated chronic medical condition or 
hemoglobin <10g% were excluded from the 
study. The subjects were divided into three 
groups: 
Group I: 30 randomly selected apparently 
healthy females. 
Group II: 30 patients with histopathologically 
proven breast cancer in early stage disease (stage 
I and II, AJCC-TNM stage). 
Group III: 30 patients with histopathologically 
proven breast cancer in advanced stage disease 
(stage III and IV, AJCC-TNM stage). 
5 mL of venous blood was collected before 
and 3 weeks after completion of treatment in 
group II and group III females and only once in 
group I females form antecubital vein under all 
aseptic conditions. Treatment modalities included 
surgery alone, surgery followed by adjuvant 
chemotherapy, surgery followed by 
chemoradiotherapy, neoadjuvant chemotherapy 
followed by adjuvan                               
                                                     
                                              
                                                   
                                               
-    C for subsequent analysis possible at the 
earliest. 
Ferritin was estimated by chemiluminiscence 
immunoassay (Advia Centaur CP, Siemens, 
Switzerland, USA) and NO was estimated 
colorimetrically by Griess reaction [11,12]. 
The results were analysed by standard statistical 
techniques which included ANOVA test for 
comparison of pre-treatment levels in all the 
                       ‘ ’          c             
groups II and III before and after treatment.  
Results 
The mean age of presentation in group I was 47.5 
years (25-75 years), group II was 48.2 years (29- 
65 years) and in group III was 47.9 years (23-75 
years). The ratio premenopausal: 
postmenopausal females in group I was 14%: 
16%, group II 12%: 18% and in group III was 
16%: 14%. In group III, one patient was 
unmarried and nulliparous, otherwise all other 
females were married and parous. All the patients 
(group II and III) were having Karnofsky 
Performance Status (KPS) 70 and above. Overall 
50% patients had tumor in upper outer quadrant, 
10% in upper inner, 13.4% in lower outer, 3.3% 
in lower inner quadrant and 23.3% in central part 
of the breast. In group II, 4 patients presented in 
stage I and 26 patients in stage II. In group III, 25 
patients presented in stage III and 5 patients in 
stage IV. Histopathologically, 29 patients in 
group II and all 30 in group III were having 
infiltrating ductal carcinoma and 1 patient in 
                        DC    P    ’           
Overall 90% (54) of patients underwent modified 
radical mastectomy and 10% (6) were unsuitable 
for surgical intervention; 56.7% (34) received 
neoadjuvant chemotherapy, 88.3% (53) adjuvant 
and 8.3% (5) received salvage chemotherapy; 
75% (45) received radical, 5% (3) palliative and 
20% (12) received no radiotherapy. About 
hormonal therapy, 48.3% (29) were administered 
tamoxifen, 33.3% (20) letrozole, 3.3% (2) 
anastrazole and 15% (9) patients were given no 
hormonal treatment. The levels of ferritin and 
NO before (all the three groups) and after 
treatment (group II and group III) are shown in 
Table 1. 
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Table 1 Serum ferritin and NO (mean ± SD) in healthy controls (group I) and early (group II) and advanced stage (group III) breast 
carcinoma before and after treatment 
 
Group I Group II Group III 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Ferritin 
(μ /L) 
33.26±16.34 
(18.7-41.8) 
73.73±42.7* 
(35.0-116.4) 
61.6±25.8*# 
(35.8-87.4) 
103.4±83.1* 
(20.3-186.5) 
84.7±38.4*# 
(46.3-123.1) 
NO 
(μ   /L) 
21.6±8.67 
(11.3-29.6) 
40.8±16.2* 
(24.6-57.0) 
27.5±12.4*§ 
(15.1-39.9) 
70.7±69.0* 
(1.7-139.7) 
27.2±12.4*§  
(14.8-39.6) 
* p value <0.001 as compared to group I. 
# p value <0.001 as compared to levels before treatment. 
§
 p value <0.05 as compared to levels before treatment. 
 
Discussion 
The levels of ferritin were found to be significantly 
raised (p<0.001) in breast cancer patients (in both 
groups) as compared to controls. After treatment, 
these levels were found to be decreased significantly 
in groups II and III. It has been reported in literature 
that ferritin levels are raised in breast and other solid 
cancers [13,14]. This increase may either be due to 
increased expression of a tumor derived protein 
which interferes with iron metabolism or due to 
non-specific effect of malignancy on 
reticulo-endothelial iron metabolism [14, 15]. The 
rise in ferritin levels is reported to be linked with 
more advanced stage breast cancer and high ferritin 
levels are associated with more advanced malignant 
phenotype [15-17]. In our study also, the levels in 
group III were significantly higher as compared to 
group II (p<0.001). 
Rise in serum ferritin levels may be attributed to 
increased iron requirement by malignant cells for 
growth and for modulation of transferrin receptor. 
Transferrin receptors on proliferating and malignant 
cells are well documented and are considered 
potential markers for identifying cells undergoing 
divisional activity and requiring the incorporation of 
additional iron [18]. Ferritin levels have been found 
raised in breast cancer tissue also [19]. In addition to 
increased synthesis by malignant cells, other causes 
of raised serum levels include presence of 
inflammation, hepatic necrosis due to metastasis and 
reduced hepatic clearance of ferritin [20].
 
All these 
factors might have been resposible for higher ferritin 
levels in advanced stage as compared to early breast 
cancer. 
The levels of nitric oxide were found raised 
(p<0.001) in both groups II and III as compared to 
group I. The difference in NO levels between group II 
and group III was also statistically significant 
(p<0.001). NO influences various aspects of tumor 
biology like modulation of cell growth, apoptosis, 
differentiation, angiogenesis and metastatic capability. 
Mechanism of action of nitric oxide involves 
inhibition of DNA syntheis, mitochondrial respiration 
and enhancement of cellular oxidative injury. This 
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increased oxidative stress may be implicated in 
increasing ferritin secretion by breast tissue [21]. 
After treatment, levels were found to decline 
significantly in both group II (p=0.002) and group III 
(0.001).  
Hypoxia, often associated with neoplastic tissues, 
is another factor which may induce ferritin as well as 
NO production [22]. NO, acting as an oxidant, may 
induce ferritin synthesis [4]. Thus, both these markers 
are sufficiently interlinked in malignant conditions 
including carcinoma breast. The tumor markers being 
presently used for breast carcinoma like CA 15-3 and 
CEA are also not specific and are found raised in 
other diseases too. The utility of these markers is 
more if analysed in conjunction with other markers 
rather than relyning on a single one [7].
 
Therefore, it is concluded that ferritin and NO may 
help in assessing the severity and monitoring of 
breast cancer patients. As both these markers are 
non-specific and their mechanism of action is 
multifactorial, these might prove more useful if 
combined with other biomarkers for breast 
carcinoma. 
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